The Editor's Roundtable: The JUPITER Trial—Initial Results and Clinical Implications
- 15 May 2009
- journal article
- conference paper
- Published by Elsevier in The American Journal of Cardiology
- Vol. 103 (10) , 1417-1425
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of JapaneseArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor TrialCirculation, 2006
- Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/lJACC, 2005
- C-Reactive Protein Levels and Outcomes after Statin TherapyNew England Journal of Medicine, 2005
- Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary EventsNew England Journal of Medicine, 2001
- Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol LevelsCirculation, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995